2442. Outcomes in ESBL Bacteremia Empirically Treated with Piperacillin/tazobactam or Carbapenems
Session: Poster Abstract Session: Treatment of AMR Infections
Saturday, October 6, 2018
Room: S Poster Hall
  • IDWeek Poster_ESBL.pdf (190.1 kB)
  • Background:

    Infections due to extended spectrum beta-lactamase (ESBL) producing bacteria are problematic due to the association with worse outcomes and limited treatment options. Carbapenems (CBPs) remain the drugs of choice for these infections due to evidence of a mortality benefit and the mixed clinical efficacy associated with piperacillin/tazobactam (PTZ) despite often reported in vitro activity. While definitive treatment for these infections has been well-defined, evidence for appropriate empiric therapy remains inconclusive. Rapid molecular assays capable of identifying ESBL markers may aid in switching to appropriate definitive therapy sooner and spare empiric carbapenem use.


    This multicenter retrospective study at 9 sites at Baylor Scott & White Health included patients with a positive blood culture with ESBL-producing bacteria identified by rapid molecular assay from 1/1/14 to 9/22/17 and were empirically prescribed either PTZ or a CBP. Patients were excluded if they continued PTZ for more than 24H after identification or did not receive a CBP for definitive therapy. Categorical data was analyzed using the Fisher’s exact test and continuous data was evaluated using the t-test and Wilcoxon rank sum test.


    117 patients met inclusion criteria of which 66 and 51 received empiric PTZ or CBPs, respectively. Baseline characteristics were similar between the groups, including suspected source of bacteremia, prior hospital stay, prior antibiotic therapy, history of positive non-blood ESBL culture, ICU admission, and time to ESBL identification. There was no difference in hospital mortality (3 vs 7.8%, p = 0.4), hospital length of stay (6.1 vs 5.9%, p = 0.88), ICU length of stay (4.7 vs 3.3%, p = 0.39) or recurrent ESBL bacteremia (7.6 vs 7.8%, p = 0.99) between those that received PTZ or a CBP for initial treatment, respectively.


    This study in patients with ESBL bacteremia showed similar outcomes when treated empirically with PTZ or a CBP. In the era of rapid molecular assays, these results suggest that empiric PTZ use and avoidance of empiric CBP therapy in the first 24H of infection can be considered until a microbiological diagnosis is confirmed.

    Reeba John, PharmD, Peter Colley, Pharm.D., BCPS, Hoa Nguyen, MD, MS, PhD and Mezgebe Berhe, MD, MPH, Baylor University Medical Center, Dallas, TX


    R. John, None

    P. Colley, None

    H. Nguyen, None

    M. Berhe, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.